Related Experiment Video

Updated: Aug 15, 2026

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Prospects for the therapeutic use of human monoclonal antibodies

J W Larrick, J M Bourla

    Journal of Biological Response Modifiers
    |October 1, 1986
    PubMed

    Despite much recent progress, human monoclonal antibodies (HuMAbs) are currently more difficult to generate than conventional rodent monoclonals. Clinical trials using rodent monoclonals suggest that they can be given safely, but that the human antimouse immune response can limit their efficacy. We review the human monoclonals that have been generated to date, and explore the clinical uses that will be made of these reagents in the near future.

    More Related Videos

    Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood13:14

    Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

    Published on: February 6, 2018

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    Related Concept Videos

    Hybridoma Technology01:31

    Hybridoma Technology

    Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
    Hybridoma Selection
    Commonly used fusion techniques — electroporation, polyethylene glycol...